Heart failure & cardiomyopathiesResearch article
Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results
- cost-utility model
- based on individual patient-level data from the IRONMAN trial
- one-year time horizon
- perspective of NHS England
- within-trial analysis
Authors' conclusion
Over a one-year time horizon, a within-trial analysis showed that administering FDI to patients with heart failure and iron deficiency was cost saving compared to usual care, driven primarily by reduced rates of hospitalisation.
Study context
- Population
- Patients with new or established heart failure, iron deficiency, and a left ventricular ejection fraction ≤45%
- Comparison
- Ferric derisomaltose (FDI) compared to usual care
Main finding
Quality-adjusted life years (QALYs) · one year
Difference
0.016 QALYs
95% credible interval CI 0.002–0.032
By group
FDI vs usual care
difference 0.016 QALYs (95% credible interval CI 0.002–0.032)
As reported in the abstract
Further findings
| Outcome | savings (per patient) (95% credible interval CI) |
|---|---|
| Costs per patient · over one year · savings with FDI; 15% less than the cost of usual care | £580 (£493-£678) |
- Costs per patient — Incremental costs of acquiring and administering FDI
- £357
- Costs per patient — Savings due to avoided hospitalisations and end-of-life care
- £936
Original publication
Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results. ESC Heart Fail. Published 14 October 2026. doi:10.1093/eschf/xvag261
Summarised from the published abstract; every number is checked against it